Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

KAVGACI, AKİF; KULA, SERDAR; İncedere, FATMA; TOKGÖZ, SEMİHA; TUNAOĞLU, FATMA

doi:10.5606/tgkdc.dergisi.2023.23748

Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

KAVGACI A., KULA S., İncedere F., TOKGÖZ S., TUNAOĞLU F. S.

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, cilt.31, sa.1, ss.145-148, 2023 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 1
Basım Tarihi: 2023
Doi Numarası: 10.5606/tgkdc.dergisi.2023.23748
Dergi Adı: TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.145-148
Anahtar Kelimeler: Pulmonary arterial hypertension, subcutaneous, treprostinil
Gazi Üniversitesi Adresli: Evet

Özet

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.